07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

SRI International autoimmune news

The U.S. Department of Defense awarded SRI a one-year grant to develop an oral inhibitor of microRNA-326 (miR-326) to treat multiple sclerosis (MS). SRI said the product is in the early stage of development....
08:00 , Jan 14, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-326 (miR-326) Studies in mice and in cell culture suggest that increasing miR-326 levels could...
07:00 , Oct 22, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) ...